Celosia cristata powder and preparation method thereof
Through the preparation method of Cycups Flower Powder, the problem of poor effect of traditional Chinese medicine antiviral agents is solved, and effective inhibition and safe and convenient prevention and treatment effects on a variety of viruses are achieved.
Patent Information
- Application Number
- CN202411024316.4
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-29
- Publication Date
- 2024-11-08
AI Technical Summary
Traditional Chinese medicine antiviral agents cannot effectively inhibit the rapid transmission of viruses and poor treatment effects, especially the prevention and treatment of multiple viruses.
A powder made of cockscomb as a raw material is prepared by soaking, decocting, extracting and crushing, forming a broad-spectrum antiviral cockscomb powder for internal use. The method includes soaking for 30 minutes, decocting for 2 hours for the first time, decocting for 2 hours for the second time, concentrating into a dry extract and crushing.
This cockscomb powder has broad-spectrum antiviral activity and can effectively inhibit the replication of various viruses. It has high safety and few side effects. It is suitable for long-term use, and is easy to take and has high cost-effectiveness. It is suitable for prevention and treatment of viral infectious diseases.
Smart Images

Figure SMS_13 
Figure HDA0004968111360000011 
Figure HDA0004968111360000021
Abstract
Description
Technical Field
[0001] The invention belongs to the technical field of traditional Chinese medicines, and in particular relates to a cockscomb flower powder and a preparation method thereof. Background Art
[0002] Traditional Chinese medicine has a significant antiviral effect in clinical practice, from Zhang Zhongjing's Baihu Decoction and Ma Xing Shi Gan Decoction in the Han Dynasty to Qingying Decoction, Yinqiao Powder, Sangju Yin in the Qing Dynasty. However, as viruses evolve and mutate, traditional Chinese medicine antiviral agents cannot effectively inhibit the rapid spread of viruses and have poor therapeutic effects on viruses. Therefore, developing a broad-spectrum antiviral Chinese medicine to prevent and treat a variety of viruses is a hot topic in current research. Summary of the invention
[0003] The technical problem to be solved by the present invention is to provide a cockscomb flower powder which has broad-spectrum antiviral activity and is easy to use, highly safe and has little side effect, and a preparation method thereof.
[0004] In order to solve the above technical problems, the present invention adopts the following technical solutions:
[0005] Cockscomb powder is made from cockscomb as raw material.
[0006] Each dose contains 13 to 17 portions of cockscomb.
[0007] Each dose contains 15 portions of Celosia cristata.
[0008] Powders are for internal use.
[0009] The preparation method of the cockscomb powder is as follows: soak the cockscomb and then boil it, filter it after boiling, concentrate the filtrate into an extract, dry the extract to make a dry extract, and grind the dry extract to obtain the powder.
[0010] The above preparation method is carried out according to the following steps:
[0011] <1> Soaking: Put the cockscomb raw materials into a sterilized container, add appropriate amount of water to allow the Chinese medicine to absorb water and swell, and soak;
[0012] <2> First decoction: add water to decoct cockscomb, filter out the first decoction;
[0013] <3> Second decoction: add water and continue decoction <2> Filter out the second medicinal juice from the medicinal residue;
[0014] <4> Preparation of extract: Combine the decoctions from the two decoctions, concentrate into an extract, and dry into a dry extract;
[0015] <5> Grinding: Grind the dry extract into fine powder, put it into a sealed container and store it in a cool and dry place.
[0016] step <1> The soaking time is 30 minutes.
[0017] step <2> or <3> Add 8 times the weight of water to the raw material and cook for 2 hours.
[0018] step <4> The relative density of the extract is 1.36 at 80°C.
[0019] The above-mentioned cockscomb powder is used in the preparation of antiviral drugs, and the viruses are P2V virus, RV virus, CV-A9 virus, CV-B3 virus, RSV virus, VACV_TT virus, EV71 virus, AdV virus, SARS virus, PEDV virus, ZIKA virus, and PV virus.
[0020] In view of the problems existing in current antiviral drugs, the inventor has developed a cockscomb powder made from cockscomb. Studies have shown that the cockscomb powder has antiviral effects against a variety of viruses. Compared with the prior art, the present invention has the following outstanding advantages:
[0021] The invention adopts natural Chinese medicinal ingredients, which are widely available, low in cost, simple in preparation method, highly safe, and with few side effects, and is suitable for long-term use.
[0022] The invention can effectively inhibit the replication of multiple viruses and has a significant effect on the prevention and treatment of common viruses.
[0023] The powder of the present invention is easy to take, does not require injection or intravenous infusion, and has a higher cost-effectiveness.
[0024] In summary, the cockscomb powder of the present invention has a broad-spectrum antiviral activity and has potential in preventing and treating viral infectious diseases. BRIEF DESCRIPTION OF THE DRAWINGS
[0025] Figure 1 The present invention is a flow chart of the preparation method of cockscomb powder.
[0026] Figure 2 This is a graph showing the results of the antiviral pharmacodynamics experiment (half effective concentration test and half cytotoxic concentration test) of the cockscomb powder of the present invention, wherein: A P2V virus; B RV virus; C CV-A9 virus; D CV-B3 virus; E RSV virus; FVACV_TT virus; G EV71 virus; H AdV virus; I SARS virus; J PEDV virus; K ZIKA virus; L PV virus. DETAILED DESCRIPTION
[0027] 1. Preparation of Cockscomb Powder
[0028] Formula: Made with cockscomb as raw material, each dose contains 15 portions of cockscomb. (Each raw material medicinal material complies with the standards of Part I of the 2020 edition of the Pharmacopoeia of the People's Republic of China)
[0029] Preparation method (such as Figure 1 shown):
[0030] <1> Soaking: Put the cockscomb raw materials into a sterilized container, add appropriate amount of water to allow the Chinese medicine to absorb water and swell, and soak for 30 minutes;
[0031] <2> First decoction: add 8 times the amount of water and boil Celosia cristata for 2 hours, filter out the first decoction;
[0032] <3> Second decoction: add 8 times the amount of water and continue decoction <2> Leave the medicine residue for 2 hours and filter out the second juice;
[0033] <4> Preparation of extract: Combine the decoctions from the two decoctions, concentrate into an extract (relative density is 1.36 at 80°C), and dry into a dry extract;
[0034] <5> Grinding: Grind the dry extract into fine powder, put it into a sealed container and store it in a cool and dry place.
[0035] Mechanism of action (speculation): Celosia enoyl, celosia glycoside and other substances in Celosia scomb have the effect of inhibiting viral replication. They can bind to the capsid protein or nucleic acid of the virus to prevent the replication and spread of the virus. At the same time, Celosia scomb can enhance the body's immune function and help the body eliminate viruses. The flavonoids, polysaccharides and other ingredients contained in Celosia scomb have immunomodulatory effects and can improve the body's antiviral ability. Not only that, Celosia scomb has an antioxidant effect, which can help eliminate free radicals in the body and prevent free radicals from damaging cells. Free radicals are products produced during the body's metabolism and can cause cell damage and inflammation, while the antioxidant components in Celosia scomb can protect cells from free radical damage. Finally, Celosia scomb has anti-inflammatory effects (such as Celosia enoyl, celosia glycoside, etc.), which can help relieve the inflammatory response caused by viral infection. Reduce tissue damage.
[0036] 2. Antiviral Pharmacodynamics Experiment
[0037] The following experiments used the cockscomb powder prepared in the above step 1 as the experimental medicine.
[0038] 1. Experimental Example 1: Anti-GX_P2V virus (i.e., P2V) pharmacodynamics experiment
[0039] 2. EC50 test: Vero E6 cells were pre-seeded in 96-well plates (2×104 cells / well) and cultured overnight. Cells were infected with GX_P2V virus at a final MOI of 0.01, and different concentrations of drugs were added at the same time. The drug concentration range was 10 mg / mL to 0.02 mg / mL, and the concentration was diluted 2 times. After 2 hours of infection, PBS was washed 3 times and the medium containing the same concentration of drugs was added, and cultured for 48 hours. Observe under a microscope, collect cell nucleic acids, and use qRT-PCR to quantify viral nucleic acids. GAPDH was used for homogenization, and the EC50 was analyzed using GraphPad Prism 8.0.
[0040] 3. Half cytotoxic concentration (CC50) test: The cytotoxicity of drugs to Vero E6 cells was measured by CellTiter-Blue assay. Specifically, Vero E6 cells were pre-seeded in 96-well plates (2×104 cells / well), and different concentrations of drugs were added after overnight culture. The drug concentration range was 10 mg / mL to 0.02 mg / mL, and the concentration was diluted 2 times. After incubation for 48 hours, 20 μL of Reagent (Promega, G8081), incubated at 37°C for 1-2 h, and then detected the fluorescence signal with an excitation wavelength of 554 nm and an emission wavelength of 593 nm. The half cytotoxic concentration (CC50) was analyzed using GraphPad Prism 8.0.
[0041] Test Example 2 Anti-VACV_TT Virus Pharmacodynamics Experiment
[0042] 1. EC50 test: Vero E6 cells were pre-seeded in 96-well plates (2×104 cells / well) and cultured overnight. The cells were infected with VACV_TT virus at a final MOI of 0.01, and different concentrations of drugs were added at the same time. The drug concentration range was 10 mg / mL to 0.02 mg / mL, and cultured for 36 hours. Observe under a microscope, collect cell nucleic acids, and quantify viral nucleic acids using qRT-PCR. GAPDH was used for homogenization, and the EC50 was analyzed using GraphPad Prism8.0.
[0043] 2. Half cytotoxic concentration (CC50) test: The cytotoxicity of drugs to Vero E6 cells was measured by CellTiter-Blue assay. Specifically, Vero E6 cells were pre-seeded in 96-well plates (2×104 cells / well), and different concentrations of drugs were added after overnight culture. The drug concentration range was 10 mg / mL to 0.02 mg / mL, and the concentration was diluted 2 times. After incubation for 36 hours, 20 μL of Reagent (Promega, G8081), incubated at 37°C for 1-2 h, and then detected the fluorescence signal with an excitation wavelength of 554 nm and an emission wavelength of 593 nm. The half cytotoxic concentration (CC50) was analyzed using GraphPad Prism 8.0.
[0044] Test Example 3 Anti-CV-A9 Virus Pharmacodynamics Experiment
[0045] 1. EC50 test: RD cells were pre-seeded in 96-well plates (2×104 cells / well) and cultured overnight. Cells were infected with CV-A9 virus at a final MOI of 0.001, and different concentrations of drugs were added at the same time. The drug concentration range was 10 mg / mL to 0.02 mg / mL, and the concentration was diluted 2 times. After 2 hours of infection, PBS was washed 3 times and the medium containing the same concentration of drugs was added, and cultured for 48 hours. Observe under a microscope, collect cell nucleic acids, and use qRT-PCR to quantify viral nucleic acids. GAPDH was used for homogenization, and the EC50 was analyzed using GraphPad Prism 8.0.
[0046] 2. Half cytotoxic concentration (CC50) test: The cytotoxicity of drugs to RD cells was measured by CellTiter-Blue assay. Specifically, RD cells were pre-seeded in 96-well plates (2×104 cells / well), and different concentrations of drugs were added after overnight culture. The drug concentration range was 10 mg / mL to 0.02 mg / mL, and the concentration was diluted 2 times. After incubation for 48 hours, 20 μL of Reagent (Promega, G8081), incubated at 37°C for 1-2 h, and then detected the fluorescence signal with an excitation wavelength of 554 nm and an emission wavelength of 593 nm. The half cytotoxic concentration (CC50) was analyzed using GraphPad Prism 8.0.
[0047] Test Example 4 Anti-ADV-5 virus (ie, AdV) pharmacodynamics experiment
[0048] 1. EC50 test: Hela cells were pre-seeded in 96-well plates (2×104 cells / well) and cultured overnight. The cells were infected with ADV-5 virus with a final MOI of 0.1, and different concentrations of drugs were added at the same time. The drug concentration range was 10 mg / mL to 0.02 mg / mL, and the concentration was diluted 2 times. After 2 hours of infection, PBS was washed 3 times and the medium containing the same concentration of drugs was added, and cultured for 48 hours. Observe under a microscope, collect cell nucleic acids, and use qRT-PCR to quantify viral nucleic acids. GAPDH was used for homogenization, and the EC50 was analyzed using GraphPad Prism 8.0.
[0049] 2. Half cytotoxic concentration (CC50) test: The cytotoxicity of drugs to Hela cells was measured by CellTiter-Blue assay. Specifically, Hela cells were pre-seeded in 96-well plates (2×104 cells / well), and different concentrations of drugs were added after overnight culture. The drug concentration range was 10 mg / mL to 0.02 mg / mL, and the concentration was diluted 2 times. After incubation for 48 hours, 20 μL of Reagent (Promega, G8081), incubated at 37°C for 1-2 h, and then detected the fluorescence signal with an excitation wavelength of 554 nm and an emission wavelength of 593 nm. The half cytotoxic concentration (CC50) was analyzed using GraphPad Prism 8.0.
[0050] Test Example 5 Anti-CV-B3 Virus Pharmacodynamics Experiment
[0051] 1. EC50 test: Vero E6 cells were pre-seeded in 96-well plates (2×104 cells / well) and cultured overnight. The cells were infected with CVB3 virus at a final MOI of 0.1, and different concentrations of drugs were added at the same time. The drug concentration range was 10 mg / mL to 0.02 mg / mL, and cultured for 24 hours. Observed under a microscope, cell nucleic acids were collected, viral nucleic acids were quantified using qRT-PCR, and GAPDH was used for homogenization. The EC50 was analyzed using GraphPad Prism 8.0.
[0052] 2. Half cytotoxic concentration (CC50) test: The cytotoxicity of drugs to Vero E6 cells was measured by CellTiter-Blue assay. Specifically, Vero E6 cells were pre-seeded in 96-well plates (2×104 cells / well), and different concentrations of drugs were added after overnight culture. The drug concentration range was 10 mg / mL to 0.02 mg / mL, and the concentration was diluted 2 times. After incubation for 24 hours, 20 μL of Reagent (Promega, G8081), incubated at 37°C for 1-2 h, and then detected the fluorescence signal with an excitation wavelength of 554 nm and an emission wavelength of 593 nm. The half cytotoxic concentration (CC50) was analyzed using GraphPad Prism 8.0.
[0053] Test Example 6 Anti-PEDV Virus Pharmacodynamics Experiment
[0054] 1. EC50 test: Vero E6 cells were pre-seeded in 96-well plates (2×104 cells / well) and cultured overnight. The cells were infected with PEDV virus at a final MOI of 0.01, and different concentrations of drugs were added at the same time. The drug concentration range was 10 mg / mL to 0.02 mg / mL, and cultured for 36 hours. Observe under a microscope, collect cell nucleic acids, and quantify viral nucleic acids using qRT-PCR. GAPDH was used for homogenization, and the EC50 was analyzed using GraphPad Prism 8.0.
[0055] 2. Half cytotoxic concentration (CC50) test: The cytotoxicity of drugs to Vero E6 cells was measured by CellTiter-Blue assay. Specifically, Vero E6 cells were pre-seeded in 96-well plates (2×104 cells / well), and different concentrations of drugs were added after overnight culture. The drug concentration range was 10 mg / mL to 0.02 mg / mL, and the concentration was diluted 2 times. After incubation for 36 hours, 20 μL of Reagent (Promega, G8081), incubated at 37°C for 1-2 h, and then detected the fluorescence signal with an excitation wavelength of 554 nm and an emission wavelength of 593 nm. The half cytotoxic concentration (CC50) was analyzed using GraphPad Prism 8.0.
[0056] Test Example 7 Anti-EV-A71 virus (i.e. EV71) pharmacodynamics experiment
[0057] 1. Half effective concentration (EC50) test: RD cells were pre-seeded in 96-well plates (2×104 cells / well) and cultured overnight. The cells were infected with EV-A71 virus with a final MOI of 0.1, and different concentrations of drugs were added at the same time. The drug concentration range was 10 mg / mL to 0.02 mg / mL, and the concentration was diluted 2 times. The cells were cultured for 24 hours. Observed under a microscope, cell nucleic acids were collected, and viral nucleic acids were quantified by qRT-PCR. GAPDH was used for homogenization, and the half effective concentration (EC50) was analyzed using GraphPad Prism 8.0.
[0058] 2. Half cytotoxic concentration (CC50) test: The cytotoxicity of drugs to RD cells was measured by CellTiter-Blue assay. Specifically, RD cells were pre-seeded in 96-well plates (2×104 cells / well), and different concentrations of drugs were added after overnight culture. The drug concentration range was 10 mg / mL to 0.02 mg / mL, and the concentration was diluted 2 times. After incubation for 24 hours, 20 μL of Reagent (Promega, G8081), incubated at 37°C for 1-2 h, and then detected the fluorescence signal with an excitation wavelength of 554 nm and an emission wavelength of 593 nm. The half cytotoxic concentration (CC50) was analyzed using GraphPad Prism 8.0.
[0059] Test Example 8 Anti-RSV Virus Pharmacodynamics Experiment
[0060] 1. EC50 test: Vero E6 cells were pre-seeded in 96-well plates (2×104 cells / well) and cultured overnight. The cells were infected with RSV virus at a final MOI of 0.01, and different concentrations of drugs were added at the same time, ranging from 10 mg / mL to 0.02 mg / mL, and cultured for 48 hours. Observe under a microscope, collect cell nucleic acids, and quantify viral nucleic acids using qRT-PCR. GAPDH was used for homogenization, and the EC50 was analyzed using GraphPad Prism 8.0.
[0061] 2. Half cytotoxic concentration (CC50) test: The cytotoxicity of drugs to Vero E6 cells was measured by CellTiter-Blue assay. Specifically, Vero E6 cells were pre-seeded in 96-well plates (2×104 cells / well), and different concentrations of drugs were added after overnight culture. The drug concentration range was 10 mg / mL to 0.02 mg / mL, and the concentration was diluted 2 times. After incubation for 48 hours, 20 μL of Reagent (Promega, G8081), incubated at 37°C for 1-2 h, and then the fluorescence signal was detected with an excitation wavelength of 554 nm and an emission wavelength of 593 nm. The half cytotoxic concentration (CC50) was analyzed using GraphPad Prism 8.0
[0062] Test Example 9 Anti-rotavirus (RV) pharmacodynamics experiment
[0063] 1. Half effective concentration (EC50) test: MA-104 cells were pre-seeded in 96-well plates (2×104 cells / well) and cultured overnight. Rotavirus was activated at 37°C for 30 min with trypsin (EDTA-free) (15050-065, Gibco) at a final concentration of 20ug / ml. Cells were infected with porcine rotavirus OSU strain at a final MOI = 0.1, and the infection maintenance solution contained 0.2% BSA (H1130, Solarbio) and 2ug / ml trypsin (EDTA-free). Different concentrations of drugs were added at the same time, with the drug concentration range of 10mg / mL to 0.02mg / mL, and cultured for 36 hours. Observe under a microscope, collect cell nucleic acids, and use qRT-PCR to quantify viral nucleic acids. GAPDH was used for homogenization, and the half effective concentration (EC50) was analyzed using GraphPad Prism 8.0.
[0064] 2. Half cytotoxic concentration (CC50) test: The cytotoxicity of drugs to MA-104 cells was measured by CellTiter-Blue assay. Specifically, MA-104 cells were pre-seeded in 96-well plates (2×104 cells / well), and different concentrations of drugs were added after overnight culture. The drug concentration range was 10 mg / mL to 0.02 mg / mL, and the concentration was diluted 2 times. After incubation for 48 hours, 20 μL of Reagent (G8081, Promega) was incubated at 37°C for 1-2 h, and the fluorescence signal was detected with an excitation wavelength of 554 nm and an emission wavelength of 593 nm. The half cytotoxic concentration (CC50) was analyzed using GraphPadPrism 8.0.
[0065] Test Example 10 Anti-SARS-CoV virus (i.e. SARS) pharmacodynamics experiment
[0066] 1. Half effective concentration (EC50) test: Huh7 cells were pre-seeded in 96-well plates (2×104 cells / well) and cultured overnight. The cells were infected with SARS-CoV virus with a final MOI of 0.1, and different concentrations of drugs were added at the same time. The drug concentration range was 10.3 mg / mL to 0.02 mg / mL of a traditional Chinese medicine, and the concentration was diluted 2 times. After 2 hours of infection, PBS was washed 3 times and the medium containing the same concentration of drugs was added, and cultured for 48 hours. Observe under a microscope, collect cell nucleic acids, and use qRT-PCR to quantify viral nucleic acids. GAPDH was used for homogenization, and the half effective concentration (EC50) was analyzed using GraphPad Prism8.0.
[0067] 2. Half cytotoxic concentration (CC50) test: The cytotoxicity of drugs to Huh7 cells was measured by CellTiter-Blue assay. Specifically, Huh7 cells were pre-seeded in 96-well plates (2×104 cells / well), and different concentrations of drugs were added after overnight culture. The drug concentration range was 10.3 mg / mL to 0.02 mg / mL, and the concentration was diluted 2 times. After incubation for 48 hours, the supernatant was removed and washed with PBS, and 100 μL of new culture medium was added and 20 μL of each well was added. Reagent (Promega, G8081), incubated at 37°C for 1-2 h, and then detected the fluorescence signal with an excitation wavelength of 554 nm and an emission wavelength of 593 nm. The half cytotoxic concentration (CC50) was analyzed using GraphPad Prism 8.0.
[0068] Test Example 11 Anti-ZIKA virus pharmacodynamics experiment
[0069] 1. EC50 test: Vero E6 cells were pre-seeded in 96-well plates (2×104 cells / well) and cultured overnight. The cells were infected with ZIKA virus at a final MOI of 0.01, and different concentrations of drugs were added at the same time. The drug concentration range was 10.3 mg / mL to 0.02 mg / mL of a traditional Chinese medicine, and the concentration was diluted 2 times. After 2 hours of infection, the PBS was washed 3 times and the medium containing the same concentration of drugs was added, and cultured for 48 hours. Observe under a microscope, collect cell nucleic acids, and use qRT-PCR to quantify viral nucleic acids. GAPDH was used for homogenization, and the EC50 was analyzed using GraphPadPrism 8.0.
[0070] 2. Half cytotoxic concentration (CC50) test: The cytotoxicity of drugs to Vero E6 cells was measured by CellTiter-Blue assay. Specifically, Vero E6 cells were pre-seeded in 96-well plates (2×104 cells / well), and different concentrations of drugs were added after overnight culture. The drug concentration range was 10.3 mg / mL to 0.02 mg / mL, and the concentration was diluted 2 times. After incubation for 48 hours, the supernatant was removed and washed with PBS, and 100 μL of new culture medium was added and 20 μL of each well was added. Reagent (Promega, G8081), incubated at 37°C for 1-2 h, and then detected the fluorescence signal with an excitation wavelength of 554 nm and an emission wavelength of 593 nm. The half cytotoxic concentration (CC50) was analyzed using GraphPad Prism 8.0.
[0071] Test Example 12 Anti-PV-1 virus (i.e. PV) pharmacodynamics experiment
[0072] 1. EC50 test: RD cells were pre-seeded in 96-well plates (2×104 cells / well) and cultured overnight. Cells were infected with PV-1 virus at a final MOI of 0.1, and different concentrations of drugs (three traditional Chinese medicines) were added at the same time. The drug concentration range was 10 mg / mL to 0.02 mg / mL, and the concentration was diluted 2 times. The cells were cultured for 24 hours. Observed under a microscope, cell nucleic acids were collected, and viral nucleic acids were quantified by qRT-PCR. GAPDH was used for homogenization, and the EC50 was analyzed using GraphPad Prism 8.0.
[0073] 2. Half cytotoxic concentration (CC50) test: The cytotoxicity of drugs (three traditional Chinese medicines) to RD cells was measured by CellTiter-Blue assay. Specifically, RD cells were pre-seeded in 96-well plates (2×104 cells / well), and different concentrations of drugs were added after overnight culture. The drug concentration range was 10 mg / mL to 0.02 mg / mL, and the concentration was diluted 2 times. After incubation for 24 hours, 20 μL of Reagent (Promega, G8081), incubated at 37°C for 1-2 h, and then detected the fluorescence signal with an excitation wavelength of 554 nm and an emission wavelength of 593 nm. The half cytotoxic concentration (CC50) was analyzed using GraphPad Prism 8.0.
[0074] 3. Results of antiviral pharmacodynamics experiments
[0075] like Figure 2 As shown, the horizontal axis is the drug concentration, and the vertical axis is the percentage of cell activity and the percentage of virus inhibition. When the drug concentration is low, the cell activity percentage is high and the virus inhibition percentage is low. As the drug concentration increases, the cell activity percentage gradually decreases and the virus inhibition percentage gradually increases. When the drug concentration reaches a certain value, the cell activity percentage drops to the lowest and the virus inhibition percentage reaches the highest. CC50 is the drug concentration that reduces cell activity by 50%, and EC50 is the drug concentration that achieves 50% virus inhibition. Table 1 shows the analysis results of the half-effective concentration and half-cytotoxic concentration of the cockscomb powder of the present invention against 12 different viruses.
[0076] Table 1 Pharmacodynamics experimental results of cockscomb powder of the present invention against 12 viruses
[0077]
Claims
1. A cockscomb powder, characterized in that Made from cockscomb.
2. The cockscomb powder according to claim 1, characterized in that Each dose contains 13 to 17 portions of cockscomb.
3. The cockscomb powder according to claim 1, characterized in that Each dose contains 15 portions of Celosia cristata.
4. The cockscomb powder according to claim 1, characterized in that: The powder is a powder for internal use.
5. The method for preparing the cockscomb powder according to claim 1, characterized in that: Soak cockscomb and then boil it. Filter it after boiling, concentrate the filtrate into an extract, dry the extract to make a dry extract, and grind the dry extract to obtain the final product.
6. The preparation method according to claim 4, characterized in that Follow these steps: <1> Soaking: Put the cockscomb raw materials into a container, add appropriate amount of water, and soak; <2> First decoction: add water to decoct cockscomb, filter out the first decoction; <3> Second decoction: add water and continue decoction <2> Filter out the second medicinal juice from the medicinal residue; <4> Preparation of extract: Combine the decoctions from the two decoctions, concentrate into an extract, and dry into a dry extract; <5> Crushing: Crush the dry extract into a fine powder.
7. The preparation method according to claim 4, characterized in that step <1> The soaking time is 30 minutes.
8. The preparation method according to claim 4, characterized in that step <2> or <3> Add 8 times the weight of water to the raw material and cook for 2 hours.
9. The preparation method according to claim 4, characterized in that step <4> The relative density of the extract is 1.36 at 80°C.
10. The use of the cockscomb powder according to claim 1 in the preparation of antiviral drugs, characterized in that: The viruses are P2V virus, RV virus, CV-A9 virus, CV-B3 virus, RSV virus, VACV_TT virus, EV71 virus, AdV virus, SARS virus, PEDV virus, ZIKA virus, and PV virus.
